KEYNOTE 671 Trial Summary Introduction:The KEYNOTE 671 trial aimed to investigate the efficacy of perioperative pembrolizumab, an immune checkpoint inhibitor, in patients with resectable early-stage non–small-cell lung cancer (NSCLC). This randomized, double-blind, phase 3 trial assessed the benefits of neoadjuvant … Read More
non small cell lung cancer
ALEX Trial Summary: Alectinib vs. Crizotinib in NSCLC
2017 ALEX TRIAL Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer international, open-label, randomised phase 3 trial Σ Objective: To compare alectinib (600 mg twice daily) with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with … Read More
Early Palliative Care in Patients with Lung Cancer Trial
2010 EARLY PALLIATIVE CARE M Early Palliative Care for Patients with Metastatic Non-Small-cell Lung Cancer Single-center, Prospective, non-blinded, parallel-group, randomized, control Objective: In patients with metastatic NSCLC, how does the early introduction of palliative care affect the quality of life? … Read More